Hallek, Michael (2017). Role and timing of new drugs in CLL. Hematol. Oncol., 35. S. 30 - 33. HOBOKEN: WILEY. ISSN 1099-1069

Full text not available from this repository.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-229031
DOI: 10.1002/hon.2397
Journal or Publication Title: Hematol. Oncol.
Volume: 35
Page Range: S. 30 - 33
Date: 2017
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1099-1069
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC LYMPHOCYTIC-LEUKEMIA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; OPEN-LABEL; FRONTLINE TREATMENT; 17P DELETION; THERAPY; CHLORAMBUCIL; PROGRESSION; RITUXIMAB; TRIALMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/22903

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item